EuroPeptides 2014

Enhance your understanding of new formulation strategies that exploit routes of administration.

Discover the latest clinical and pre-clinical programme updates.

Uncover the cutting edge developments in macrocyclic and constrained peptides.

Evaluate new techniques to improve solid phase peptide synthesis including microwave-assisted SPPS and optimise large scale peptide manufacturing.

Optimise your manufacturing and analytical strategy to ensure successful and cost-effective process development stages.

Identify promising novel targets and indications outside of diabetes to help the expansion of pipelines in drug development.

Explore alternative methods to improve the half life capabilities of your peptide product.

On Tuesday November 18, 2014 at 8:00 am (ends Wednesday November 19, 2014 at 5:00 pm)

URLs:

Booking: http://atnd.it/13528-0
Inquiries: http://atnd.it/13528-1

Speakers: Lars Fogh Iversen Executive Vice President Novo Nordisk, Horst Kessler Emeritus of Excellence Institute for Advanced Study at the Technische Universität München, Waleed Danho, Former, Distinguished Research Leader Roche, Dinesh Patel President & CEO Protagonist Therapeutics, Angelika Fretzen Vice President of Pharmaceutical Chemistry & Development, Ironwood Pharmaceuticals, Michael Shapiro Director, Analytical Research Technologies Pfizer Pharmaceuticals, Andy Lewis Director, Novel Delivery Technologies - CMC & Engineering-Peptides - Technical Operations Ipsen, Joël Richard Senior Vice President, Peptides - CMC & Engineering - Technical Operations Ipsen, Roger New Co-founder & Director Proxima Concepts Ltd, Adrian Podmore Formulation Scientist MedImmune, Lutz Jermutus Senior Director, R&D & Product Development Team Leader, Cardiovascular & Metabolic Diseases iMED MedImmune Ltd, Matthias Urmann Associate Vice President, Research & Translational Medicine, Insulin & Peptides, R&D, Diabetes, Division Sanofi-Aventis Deutschland GmbH, Oliver Demmer Scientist, Medicinal Chemistry Zealand Pharma, Kristopher Josephson Director of Molecular Biology RA Pharmaceuticals Inc, Eva Altmann Senior Investigator Novartis Institute for Biomedical Research, Vadim Dudkin Associate Director Centyrex, Janssen R&D, Thomas Meier Vice-President Production Bachem AG, Jon Rasmussen Director, Global Development PolyPeptide, Andreas Rybka Head of Peptide Chemistry Nexigen GmbH, Knud Jensen Professor of Nanobioscience, Department of Chemistry University of Copenhagen, Cyrille Gineste Chief Scientific Officer Riogin Corp, Lars Friedrich Scientist XL-Protein GmbH, Volker Schellenberger President and CEO Amunix Operating Inc, Carsten Grötzinger Group Leader, Hepatology & Gastroenterology Department Charite Universitatsmedizin Berlin, Sebastian Dziadek Development Leader R&D, PHC Assay Development Roche Diagnostics GmbH, Vincent Bille Founder & Managing Director Marble Pharma Consult SPRL, Gert Moll CSO Lanthio Pharma, Prof. Dr. Dieter Willbold Director Institut für Physikalische Biologie, Heinrich-Heine-Universität, Director, Institute of Complex Systems, ICS-6: Structural Biochemistry, Research Centre Jülich, Jülich, Karin Thevissen Industrial Research Manager KU Leuven, Joachim Feldwisch Director Preclinical Development Affibody, Eva Altmann Senior Investigator Novartis Institute for Biomedical Research, Prof. Charles Deber Senior Scientist, Division of Molecular Structure & Function, Research Institute Hospital for Sick Children, Professor, Department of Biochemistry, University of Toronto, Konrad Bleicher, Medicinal Chemistry Peptide Area Head, pRED, Roche Innovation Centre Basel F. Hoffmann-La Roche, Bruce Morimoto Executive Director, Applied Translational Medicine Celerion, Dan Teufel Head of Chemistry Bicycle Therapeutics, Professor David Craik Group Leader, Institute for Molecular Bioscience The University of Queensland